No profile data available.
International Isotopes Inc. (INIS) is a healthcare company in the additional hormone and metabolic drugs industry, based in Idaho Falls, United States, with about 41 full-time employees.
It reported revenue of $13.07 million for fiscal year 2025, down 6.0% from fiscal year 2024, and net income of -$908,002. Its largest business segment, Theranostics Products, brought in 52% of segment revenue in fiscal year 2025. Its market capitalization was $33.22 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally.
International Isotopes reported $13.07 million in revenue for fiscal year 2025, down 6.0% from $13.90 million in fiscal year 2024.
Theranostics Products, with $6.84 million or 52% of segment revenue in fiscal year 2025. Next: Calibration & Reference Products (33%) and Cobalt Products (13%).
$33.22 million as of December 4, 2025.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Arbutus Biopharma Corporation (ABUS), Rezolute, Inc. (RZLT), Spruce Biosciences, Inc. (SPRB), Lipocine Inc. (LPCN).